Genome editing CRISPR-based therapeutic / Editas Medicine - LARVOL DELTA

Editas Medicine presents pre-clinical data supporting the use of CRISPR-Cas12a to edit induced pluripotent stem cells for the development of engineered cell immunotherapies (GlobeNewswire) - "Editas Medicine, Inc....announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a (EngCas12a) in induced pluripotent stem cells (iPSCs) for the development of engineered cell immunotherapy medicines. The results of this study further reinforce Editas Medicine’s belief in the transformative potential of iPSC-derived natural killer (iNK) cells as off-the-shelf engineered cell medicines for the treatment of solid tumor cancers."

Preclinical • Oncology

Panel: Safety and efficacy of CRISPR moving into patients (ARVO 2018) - "Presentation Description Panelist"

Clinical • Biosimilar

"Editas founder Katrine Bosley abruptly steps aside from the helm, just ahead of a historic CRISPR move https://t.co/4wZg29MXkB" (@endpts)